We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Poster Presentations: American Head and Neck Society |

P231 The Identification of Epidermal Fatty Acid Binding Protein in Advanced Head and Neck Cancer Using a Proteomic Approach

M. Gillespie; J. Downie; T. A. Day; J. D. Hornig; B. Oswald; J. Arthur
Arch Otolaryngol Head Neck Surg. 2006;132(8):911. doi:10.1001/archotol.132.8.911-a.
Text Size: A A A
Published online


Objective: To identify proteins overexpressed in metastatic head and neck cancers using a proteomic approach.

Design: We identified differential protein expression in 10 head and neck tumors with lymph node metastasis and 3 head and neck tumors without metastasis using 2-dimensional gel separation techniques and Western blot analysis.

Results: A protein of interest, which was present in 12 (92%) of the 13 tumors, demonstrated significantly greater expression in metastatic primary tumors. The protein spot was identified as epidermal fatty acid binding protein (E-FABP) using matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) and sequenced with an ion trap mass spectrometer. Subsequent Western blot analysis of head and neck tumors using an anti–E-FABP antibody demonstrated heavy expression in 3 of 3 patients with N2 or greater neck disease and lower levels of expression in tumors with N1 (n = 1) or N0 disease (n = 2). Normal control oral mucosa demonstrated light (n = 2) or no staining (n = 3). Due to its low molecular weight, E-FABP is filtered by the kidney. Western blot analysis of patient urine detected E-FABP in the urine of 5 (83%) of 6 patients with head and neck cancer.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections